Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes.
about
Lost in translation: endoplasmic reticulum stress and the decline of β-cell health in diabetes mellitusExcess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agentsEffects of Imatinib Mesylate (Gleevec) on human islet NF-kappaB activation and chemokine production in vitroThe tyrphostin agent AG490 prevents and reverses type 1 diabetes in NOD miceSmall-molecule inhibition of inflammatory β-cell death.Influence of Tyrphostin AG490 on the expression of diabetes-associated markers in human adipocytes.Expression profiling pre-diabetic mice to uncover drugs with clinical application to type 1 diabetes.The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events.Transformation of nonfunctioning pancreatic neuroendocrine carcinoma cells into insulin producing cells after treatment with sunitinibNew approaches to the treatment of nephropathy in diabetes.Treating patients with metastatic renal carcinoma: an escape from Phase III.Does the small tyrosine kinase inhibitor Imatinib mesylate counteract diabetes by affecting pancreatic islet amyloidosis and fibrosis?Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor.Imatinib prevents beta cell death in vitro but does not improve islet transplantation outcome.Imatinib mesylate stimulates low-density lipoprotein receptor-related protein 1-mediated ERK phosphorylation in insulin-producing cells.Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5'-phosphatase interaction with c-Abl.Tyrphostin AG490 agent modestly but significantly prevents onset of type 1 in NOD mouse; implication of immunologic and metabolic effects of a Jak-Stat pathway inhibitor.Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes.Deletion of platelet-derived growth factor receptor-β improves diabetic nephropathy in Ca²⁺/calmodulin-dependent protein kinase IIα (Thr286Asp) transgenic mice.Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor
P2860
Q26864403-5C7B8506-18C7-42FF-976A-C8E640EC4C33Q28075692-DA21223C-0DEB-41A4-B8E5-AE160887D0ECQ28477081-071F0AFD-5AE9-459D-9EC1-7275D5DFBFFFQ28483660-43E7E6F2-A601-4AD6-B5BD-A9245BFEC290Q34978002-793599FF-B2D7-4C9A-BC51-D58985DD2C43Q35962215-707A5108-F2BE-4815-A937-B5A66E606E86Q36022067-F8DA9812-87C4-44AA-94A9-0B43F2153063Q37117596-5B703414-DF8D-4785-9985-6691B0A3526AQ37264480-A12D5FE9-DBDF-4891-A623-19FCF3E2A142Q37899907-8D4BD4B7-14B6-414B-AAC4-841D392E0085Q38030592-6F04A186-8B6D-4E97-878F-BF2EC9711798Q38045474-5725ABC1-46A1-47EC-B1C2-BD422EACDC5EQ38110320-46979B9C-84C0-4ACA-8D4D-FDF89FA4479CQ42087175-10738A35-0888-4C93-BD6E-FEB0C656B380Q42459554-11358809-590E-4143-B858-A0DEA4CAA363Q46910956-B2E2AB12-951C-403B-B020-9662EE020707Q51334647-F42CB9DE-8C6B-42ED-8B89-305A0904F9D3Q51356447-8FB4E975-9531-4689-87B6-698E2C8D5DFDQ54568475-D449BD95-52C8-4140-81E7-DBF896668EBDQ58613635-8EEF7CC1-8BF1-4047-8D10-7A3EE3E4C5B5
P2860
Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes.
@en
Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes.
@nl
type
label
Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes.
@en
Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes.
@nl
prefLabel
Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes.
@en
Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes.
@nl
P2860
P356
P1433
P1476
Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes.
@en
P2093
Dariush Mokhtari
Nils Welsh
P2860
P304
P356
10.1042/CS20090348
P407
P577
2009-11-09T00:00:00Z